Microbiome-based oral therapy for gut GVHD after stem cell transplant

Who could benefit from this research

What this research studies

For people who have undergone allogeneic hematopoietic cell transplantation, this project explores an oral gut-directed therapy to modify the microbiome and potentially reduce gut GVHD symptoms. The study builds on prior work suggesting that restoring microbial balance can influence GVHD outcomes, aiming to offer a non-immunosuppressive option. It uses a carefully designed live biotherapeutic product to target the GI tract and monitor safety, microbiome changes, and clinical signals of GVHD response. If successful, this approach could complement current treatments and lessen infection risk while supporting immune recovery.

Why it matters

Where this research is happening

• Sloan-Kettering Inst Can Research
  New York, United States Active

Researchers

• Principal investigator: Ponce, Doris — Sloan-Kettering Inst Can Research
• Study coordinator: Ponce, Doris

Related research

Other NIH-funded projects on the same topics.

• Targeting early oral GVHD to improve mouth health after stem cell transplant

  A study at UW–Madison will explore why some transplant patients develop painful oral GVHD and test ideas to prevent and lessen mouth-related problems.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11616478

• Microbiome-based therapy for treatment-refractory GVHD after stem cell transplant

  A microbiome-based therapy is being developed to help people who have graft-versus-host disease that doesn’t respond to standard treatments after a stem cell transplant.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11425530

• Role of altered mitochondria in preventing GVHD after stem cell transplant

  This NIH grant explores how damaged mitochondria released during pre-transplant conditioning may trigger graft-versus-host disease and tests ways to fix mitochondrial dynamics to prevent GVHD.

  NIH research Stanford University · Stanford, United States · NIH-11378688

• Fecal transplant plus fiber to treat graft-versus-host disease after blood stem cell transplant

  A study to see if giving fecal transplant along with dietary fiber helps gut health and reduces complications in patients who have received a stem cell transplant and developed graft-versus-host disease.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-11377663

• Using medium-chain fatty acids and a fat-sensing receptor to treat chronic graft-versus-host disease

  This project looks at whether changing medium‑chain fatty acids or blocking a fat sensor called GPR84 can help people with chronic graft‑versus‑host disease after a bone marrow/stem cell transplant.

  NIH research University of Central Florida · Orlando, United States · NIH-11325709

• How the protein ID3 controls donor T cells that cause GVHD and fight leukemia

  Researchers are looking at whether changing the activity of a protein called ID3 in donor T cells can lower graft-versus-host disease while keeping those cells able to attack leukemia after a stem cell transplant.

  NIH research Hackensack University Medical Center · Hackensack, United States · NIH-11317224

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.